LeserbriefKommentar
Intrapartum Azithromycin vs Placebo for Neonatal Sepsis—Reply
JAMA · 2023
DOI: 10.1001/jama.2023.8331 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Anna Roca und 3 weiteren Autor:innen. Beteiligte Einrichtung: MRC Unit The Gambia, London School of Hygiene and Tropical Medicine, Fajara, The Gambia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Neonatal Sepsis. Die Arbeit nennt 3 Literaturangaben.
Themen: Sepsis
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Anti-Bacterial AgentsAzithromycinNeonatal SepsisFemaleHumansInfant, NewbornPregnancyPeripartum Period
Substanzen
Anti-Bacterial AgentsAzithromycin
Autor:innen und Institutionen
- MRC Unit The Gambia, London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
- Institut de Recherche en Sciences de la Santé-Clinical Research Unit of Nanoro, Nanoro, Burkina Faso.
Zitieren
APA
Roca, A., Camara, B., Tinto, H., & PregnAnZI-2 Working Group (2023). Intrapartum Azithromycin vs Placebo for Neonatal Sepsis—Reply. JAMA. https://doi.org/10.1001/jama.2023.8331
Vancouver
Roca A, Camara B, Tinto H, PregnAnZI-2 Working Group. Intrapartum Azithromycin vs Placebo for Neonatal Sepsis—Reply. JAMA. 2023. doi:10.1001/jama.2023.8331
BibTeX
@article{Roca2023,
author = {Roca, Anna and Camara, Bully and Tinto, Halidou and PregnAnZI-2 Working Group, PregnAnZI-2 Working Group},
title = {Intrapartum Azithromycin vs Placebo for Neonatal Sepsis—Reply},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.8331}
}
EUVIMED